These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 25491733)

  • 21. Skills training groups for men with ADHD in compulsory care due to substance use disorder: a feasibility study.
    Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
    Atten Defic Hyperact Disord; 2016 Sep; 8(3):159-72. PubMed ID: 27059489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.
    Tamm L; Trello-Rishel K; Riggs P; Nakonezny PA; Acosta M; Bailey G; Winhusen T
    J Subst Abuse Treat; 2013 Feb; 44(2):224-30. PubMed ID: 22889694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.
    Torgersen T; Gjervan B; Rasmussen K; Vaaler A; Nordahl HM
    Atten Defic Hyperact Disord; 2013 Mar; 5(1):59-67. PubMed ID: 23104523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills.
    Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
    BMC Psychiatry; 2013 Dec; 13():336. PubMed ID: 24330331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study.
    Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
    J Subst Abuse Treat; 2015 Apr; 51():82-90. PubMed ID: 25491733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
    Schubiner H
    CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review.
    Schubiner H; Tzelepis A; Isaacson JH; Warbasse LH; Zacharek M; Musial J
    J Clin Psychiatry; 1995 Apr; 56(4):146-50. PubMed ID: 7713853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.
    Cunill R; Castells X; Tobias A; Capellà D
    J Psychopharmacol; 2015 Jan; 29(1):15-23. PubMed ID: 25142405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of ADHD and its treatment on substance abuse in adults.
    Wilens TE
    J Clin Psychiatry; 2004; 65 Suppl 3():38-45. PubMed ID: 15046534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
    Kollins SH
    J Atten Disord; 2008 Sep; 12(2):115-25. PubMed ID: 18192623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD).
    Perugi G; Pallucchini A; Rizzato S; De Rossi P; Sani G; Maremmani AG; Pinzone V; Maremmani I
    Expert Opin Pharmacother; 2019 Feb; 20(3):343-355. PubMed ID: 30513231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Substance use disorders and ADHD: an overview of recent Dutch research].
    van Emmerik-van Oortmerssen K; Crunelle CL; Carpentier PJ
    Tijdschr Psychiatr; 2013; 55(11):861-6. PubMed ID: 24242145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder.
    Regnart J; Truter I; Meyer A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):275-282. PubMed ID: 28686107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
    NIH Consens Statement; 1998 Nov 16-18; 16(2):1-37. PubMed ID: 10868163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The course of attention deficit hyperactivity disorder (ADHD) over the life span].
    Koumoula A
    Psychiatriki; 2012 Jun; 23 Suppl 1():49-59. PubMed ID: 22796973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Attention-deficit/hyperactivity disorder and substance abuse].
    Davids E; Gastpar M
    Psychiatr Prax; 2003 May; 30(4):182-6. PubMed ID: 12768521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Awareness of adult attention-deficit/hyperactivity disorder (ADHD) in Greece].
    Pehlivanidis A
    Psychiatriki; 2012 Jun; 23 Suppl 1():60-5. PubMed ID: 22796974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders.
    Bukstein OG
    Expert Rev Neurother; 2006 Apr; 6(4):541-9. PubMed ID: 16623653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.